hrcak mascot   Srce   HID

Pregledni rad

MEMBRANOUS GLOMERULONEPHRITIS – RECENT ADVANCES IN PATHOGENESIS AND TREATMENT

Ivica Horvatić
Krešimir Galešić

Puni tekst: hrvatski, pdf (1 MB) str. 0-0 preuzimanja: 118* citiraj
APA 6th Edition
Horvatić, I. i Galešić, K. (2012). MEMBRANSKI GLOMERULONEFRITIS – NOVOSTI U PATOGENEZI I LIJEČENJU. Liječnički vjesnik, 134 (11-12), 0-0. Preuzeto s https://hrcak.srce.hr/172454
MLA 8th Edition
Horvatić, Ivica i Krešimir Galešić. "MEMBRANSKI GLOMERULONEFRITIS – NOVOSTI U PATOGENEZI I LIJEČENJU." Liječnički vjesnik, vol. 134, br. 11-12, 2012, str. 0-0. https://hrcak.srce.hr/172454. Citirano 20.10.2019.
Chicago 17th Edition
Horvatić, Ivica i Krešimir Galešić. "MEMBRANSKI GLOMERULONEFRITIS – NOVOSTI U PATOGENEZI I LIJEČENJU." Liječnički vjesnik 134, br. 11-12 (2012): 0-0. https://hrcak.srce.hr/172454
Harvard
Horvatić, I., i Galešić, K. (2012). 'MEMBRANSKI GLOMERULONEFRITIS – NOVOSTI U PATOGENEZI I LIJEČENJU', Liječnički vjesnik, 134(11-12), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172454 (Datum pristupa: 20.10.2019.)
Vancouver
Horvatić I, Galešić K. MEMBRANSKI GLOMERULONEFRITIS – NOVOSTI U PATOGENEZI I LIJEČENJU. Liječnički vjesnik [Internet]. 2012 [pristupljeno 20.10.2019.];134(11-12):0-0. Dostupno na: https://hrcak.srce.hr/172454
IEEE
I. Horvatić i K. Galešić, "MEMBRANSKI GLOMERULONEFRITIS – NOVOSTI U PATOGENEZI I LIJEČENJU", Liječnički vjesnik, vol.134, br. 11-12, str. 0-0, 2012. [Online]. Dostupno na: https://hrcak.srce.hr/172454. [Citirano: 20.10.2019.]

Sažetak
Membranous glomerulonephritis is one of the leading causes of nephrotic syndrome in adults. It may have very variable course, with some patients slowly progressing to renal failure and some entering spontaneous remission. The aim of this article is to review recent advances in the pathogenesis and treatment of the disease in recent years. In recent years, first human podocyte autoantigens, responsible for autoantibodies and in situ immune complexes formation, were discovered: neutral endopeptidase, m-type phospholipase A2receptor, superoxide-dismutase 2, aldose-reductase, a-enolase. It is postulated that these discoveries will help in differentiation between primary and secondary membranous glomerulonephritis, in predicting remission and/or relapse and also in determining more specific therapy. There have been also some pilot studies recently, in which new drugs have been introduced in the treatment of membranous glomerulonephritis: ACTH, rituximab and tacrolimus.

Ključne riječi
Glomerulonephritis, membranous – immunology, drug therapy; Autoantigens – immunology; Autoantibodies – immunology; Podocytes – immunology; Receptors, phospholipase A2 – immunology; Immunosuppressive agents – therapeutic use

Hrčak ID: 172454

URI
https://hrcak.srce.hr/172454

[hrvatski]

Posjeta: 384 *